Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert Swanson is active.

Publication


Featured researches published by Robert Swanson.


Antimicrobial Agents and Chemotherapy | 2003

Randomized Double-Blind Study Comparing 3- and 6-Day Regimens of Azithromycin with a 10-Day Amoxicillin-Clavulanate Regimen for Treatment of Acute Bacterial Sinusitis

Dan C. Henry; Ernie Riffer; William N. Sokol; Naumann I. Chaudry; Robert Swanson

ABSTRACT A randomized, double-blind, multicenter study of adults with acute bacterial sinusitis (ABS) compared the efficacy and safety of two azithromycin (AZM) regimens, 500 mg/day once daily for 3 days (AZM-3) or 6 days (AZM-6) to the efficacy and safety of an amoxicillin-clavulanate (AMC) regimen of 500-125 mg three times daily for 10 days. A total of 936 subjects with clinically and radiologically documented ABS were treated (AZM-3, 312; AZM-6, 311; AMC, 313). Clinical success rates were equivalent among per-protocol subjects at the end of therapy (AZM-3, 88.8%; AZM-6, 89.3%; AMC, 84.9%) and at the end of the study (AZM-3, 71.7%; AZM-6, 73.4%; AMC, 71.3%). Subjects treated with AMC reported a higher incidence of treatment-related adverse events (AE) (51.1%) than AZM-3 (31.1%, P < 0.001) or AZM-6 (37.6%, P < 0.001). More AMC subjects discontinued the study (n = 28) than AZM-3 (n = 7) and AZM-6 (n = 11) subjects. Diarrhea was the most frequent treatment-related AE. AZM-3 and AZM-6 were each equivalent in efficacy and better tolerated than AMC for ABS.


Antimicrobial Agents and Chemotherapy | 2014

Novel Antifungal Drug Discovery Based on Targeting Pathways Regulating the Fungus-Conserved Upc2 Transcription Factor

Christina Gallo-Ebert; Melissa Donigan; Ilana L. Stroke; Robert Swanson; Melissa T. Manners; Jamie Francisco; Geoffrey Toner; Denise Gallagher; Chia-Yu Huang; Scott E. Gygax; Maria L. Webb; Joseph T. Nickels

ABSTRACT Infections by Candida albicans and related fungal pathogens pose a serious health problem for immunocompromised patients. Azole drugs, the most common agents used to combat infections, target the sterol biosynthetic pathway. Adaptation to azole therapy develops as drug-stressed cells compensate by upregulating several genes in the pathway, a process mediated in part by the Upc2 transcription factor. We have implemented a cell-based high-throughput screen to identify small-molecule inhibitors of Upc2-dependent induction of sterol gene expression in response to azole drug treatment. The assay is designed to identify not only Upc2 DNA binding inhibitors but also compounds impeding the activation of gene expression by Upc2. An AlphaScreen assay was developed to determine whether the compounds identified interact directly with Upc2 and inhibit DNA binding. Three compounds identified by the cell-based assay inhibited Upc2 protein level and UPC2-LacZ gene expression in response to a block in sterol biosynthesis. The compounds were growth inhibitory and attenuated antifungal-induced sterol gene expression in vivo. They did so by reducing the level of Upc2 protein and Upc2 DNA binding in the presence of drug. The mechanism by which the compounds restrict Upc2 DNA binding is not through a direct interaction, as demonstrated by a lack of DNA binding inhibitory activity using the AlphaScreen assay. Rather, they likely inhibit a novel pathway activating Upc2 in response to a block in sterol biosynthesis. We suggest that the compounds identified represent potential precursors for the synthesis of novel antifungal drugs.


Bioorganic & Medicinal Chemistry Letters | 2011

Structure–activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonists

Ronald Palin; Lynn Abernethy; Nasrin Ansari; Ken Cameron; Thomas R. Clarkson; Maureen Dempster; David Dunn; Anna-Marie Easson; Darren Edwards; John Maclean; Katy Everett; Helen Feilden; Koc-Kan Ho; Steve Kultgen; Peter Littlewood; Duncan McArthur; Deborah McGregor; Hazel McLuskey; Irina Neagu; Stuart Neale; Lesley-Anne Nisbet; Michael Ohlmeyer; Quynhchi Pham; Paul Ratcliffe; Yajing Rong; Andrew Roughton; Melanie Sammons; Robert Swanson; Heather Tracey; Glenn Walker

Optimisation of a screening hit incorporating both TRPV1 activity and solubility was conducted. Substitution of the isoxazole-3-carboxamide with the bespoke 1S, 3R-3-aminocyclohexanol motif afforded the requisite balance of potency and solubility. Compounds 32 and 40 were found to have antihyperalgesic effects in the rat CFA Hg assay and induce a mechanism based hyperthermia.


Gene | 2000

Combinatorial gene expression using multiple episomal vectors

Robert A. Horlick; Adriane Schilling; Philippe Samama; Robert Swanson; V.Danial Fitzpatrick; Alan K. Robbins; Bassam Damaj

Episomal vectors offer a powerful alternative to integrative recombination for transgene expression in mammalian cells. In this study, various combinations of G protein-coupled receptors (GPCRs) and the G protein subunit G(i2)alpha, were stably expressed from separate episomal vectors in 293-EBNA (293E) cells. Each episome did not adversely affect the others, as gauged by episomal copy number, steady-state mRNA levels and the presence of functional receptors and G protein. Cell lines expressing genes from multiple autonomously replicating vectors were stable just two weeks after transfection, and remained stable in continuous culture for at least 5months. Co-expression of supplementary G(i2)alpha with receptor amplifies the magnitude of signal transduction thereby permitting the development of more sensitive high throughput functional assays. Given these results, combinatorial transfection is the strategy of choice for generating stable cell lines expressing multiple genes for the study of signal-transduction pathways or the evaluation of receptor ligands.


Bioorganic & Medicinal Chemistry Letters | 2011

Discovery of potent, soluble and orally active TRPV1 antagonists. Structure-activity relationships of a series of isoxazoles.

Paul Ratcliffe; Lynn Abernethy; Nasrin Ansari; Kenneth S. Cameron; Tom Clarkson; Maureen Dempster; David Dunn; Anna-Marie Easson; Darren Edwards; Katy Everett; Helen Feilden; Koc-Kan Ho; Steve Kultgen; Peter Littlewood; John Maclean; Duncan McArthur; Deborah McGregor; Hazel McLuskey; Irina Neagu; Olaf Nimz; Lesley-Anne Nisbet; Michael Ohlmeyer; Ronnie Palin; Quynhchi Pham; Yajing Rong; Andrew Roughton; Melanie Sammons; Robert Swanson; Heather Tracey; Glenn Walker

Systematic optimisation of a poorly soluble lead series of isoxazole-3-carboxamides was conducted. Substitution of the 4-position with specific polar functionality afforded the requisite balance of potency, solubility and physicochemical properties. Compound 21a was found to be efficacious in the rat Capsaicin Hargreaves assay following oral administration.


Assay and Drug Development Technologies | 2003

1,536-well assay development and screening using whole cell displacement binding and laser scanning imaging.

Douglas S. Auld; David Dunn; John M. Lehrach; Paul M. McCoy; Robert Swanson

A screen of a GPCR against Pharmacopeias combinatorial libraries was performed using 1,536-well plates in a 1.5-microl assay volume with an LSI that was specially modified to enable detection at these volumes. The screen encompassed approximately 4 x 10(6) compounds. The assay uses a CHO cell line that expresses human CXCR1. The plate format chosen was the Corning 1536 low-profile wafer plate. The performance of the screen is evaluated, and the necessity to obtain cytotoxicity data from the same well is described.


Bioorganic & Medicinal Chemistry | 2006

Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists

Jun Chiba; Gensuke Takayama; Tohru Takashi; Mika Yokoyama; Atsushi Nakayama; John J. Baldwin; Edward Mcdonald; K.J.M. Moriarty; Christopher R. Sarko; Kurt W. Saionz; Robert Swanson; Zahid Hussain; Angela Wong; Nobuo Machinaga


Antimicrobial Agents and Chemotherapy | 1999

Pharmacokinetics of Ampicillin and Sulbactam in Pediatric Patients

Milap C. Nahata; Vijay I. Vashi; Robert Swanson; Michael A. Messig; Menger Chung


Bioorganic & Medicinal Chemistry Letters | 2005

Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist

Jun Chiba; Nobuo Machinaga; Tohru Takashi; Akio Ejima; Gensuke Takayama; Mika Yokoyama; Atsushi Nakayama; John J. Baldwin; Edward Mcdonald; Kurt W. Saionz; Robert Swanson; Zahid Hussain; Angela Wong


Archive | 2001

Orthologues of human receptors and methods of use

Robert A. Horlick; Jiuquao Zhao; Robert Swanson; Maria L. Webb; Barbara Strohl; John J. Baldwin; Douglas S. Auld

Collaboration


Dive into the Robert Swanson's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge